THOMAS P. RICE - Corporate Board Profile

CHEMED CORP

Filing Date	Source Excerpt
2012-04-03	Mr. Rice’s experience, qualifications, attributes and skills include having served as Chief Executive Officer of Andrx Corporation. He is a Director of Par Pharmaceuticals. He serves on the Audit Committee. In 2011, Mr. Rice received $60,066 in the form of a fully vested stock award and total compensation of $136,566.
2013-04-05	Mr. Rice’s experience, qualifications, attributes and skills include having served as Chief Executive Officer of Andrx Corporation... In May 2012, Messrs. Gemunder, Grace, Krebs, Rice, Saunders and Wood and Ms. Lindell each received $60,045 in the form of a fully vested stock award of 1,086 shares of Capital Stock.
2014-04-04	Mr. Rice’s experience, qualifications, attributes and skills include having served as Chief Executive Officer of Andrx Corporation.
2015-04-07	Mr. Rice’s experience, qualifications, attributes and skills include having served as Chief Executive Officer of Andrx Corporation. He is a member of the Audit Committee. In 2014, Mr. Rice received $153,244 in compensation.
2016-04-07	Thomas P. Rice Director since May 2009 Age: 66 Mr. Rice’s experience, qualifications, attributes and skills include having served as Chief Executive Officer of Andrx Corporation. In May 2015, Messrs. Gemunder, Grace, Krebs, Rice, Saunders, Walsh and Wood and Ms. Lindell each received $60,023 in the form of a fully vested stock award of 493 shares of Capital Stock. In 2015, the Company provided the following compensation to directors and directors emeriti for their service to the Company: Thomas P. Rice 153,523
2017-04-10	Thomas P. Rice Director since May 2009 Age: 67. Mr. Rice’s experience, qualifications, attributes and skills include having served as Chief Executive Officer of Andrx Corporation ... The following table shows the current membership of each committee ... T. P. Rice Audit Committee x, Nominating Committee Chair x ... In 2016, Mr. Rice received $60,102 in the form of a fully vested stock award ... Director Compensation - 2016 ... Thomas P. Rice 87,500 Fees Earned or Paid in Cash, 66,102 Stock Awards, Total 153,602.
2018-04-11	Thomas P. RiceDirector since May 2009 Age: 68. Mr. Rice’s experience, qualifications, attributes and skills include having served as Chief Executive Officer of Andrx Corporation. ... In May 2017, Messrs. Gemunder, Grace, Krebs, Rice, Saunders, Walsh and Wood and Ms. Lindell each received $85,071 in the form of a fully vested stock award of 418 shares of Capital Stock. ... In 2017, the Company provided the following compensation to directors and directors emeriti for their service to the Company: Thomas P. Rice Fees Earned or Paid In Cash: 87,500, Stock Awards: 91,071, Total: 178,571.
2019-04-09	Thomas P. RiceDirector since May 2009 Age: 69 Mr. Rice’s experience, qualifications, attributes and skills include having served as Chief Executive Officer of Andrx Corporation, Fort Lauderdale, Florida (specialty pharmaceuticals) ... The Board and the Nominating Committee affirmatively determined that, under the New York Stock Exchange listing standards, the following directors and nominees, constituting a majority of the individuals nominated for election as directors at the Annual Meeting, are independent of the Company and its management: Messrs. Gemunder, Grace, Krebs, Rice, Saunders, Walsh and Wood and Ms. Lindell. ... In May 2018, Messrs. Gemunder, Grace, Krebs, Rice, Saunders, Walsh and Wood and Ms. Lindell each received $85,106 in the form of a fully vested stock award of 255 shares of Capital Stock. ... DIRECTOR COMPENSATION - 2018 ... Thomas P. Rice ... 89,500 ... 91,106 ... 180,606 ...
2020-04-09	Mr. Rice’s experience, qualifications, attributes and skills include having served as Chief Executive Officer of Andrx Corporation.
2021-04-09	Mr. Rice’s experience, qualifications, attributes and skills include having served as Chief Executive Officer of Andrx Corporation. In May 2020, Messrs. DeLyons, Gemunder, Grace, Heaney, Rice, Saunders, and Walsh and Ms. Lindell each received approximately $130,000 in the form of a fully vested stock award of 279 shares of Capital Stock. In 2020, the Company provided the following compensation to directors and directors emeriti for their service to the Company: Thomas P. Rice: $228,301.
2022-04-08	Mr. Rice’s experience, qualifications, attributes and skills include having served as Chief Executive Officer of Andrx Corporation, Fort Lauderdale, Florida (specialty pharmaceuticals).
2023-04-06	Thomas P. Rice Director since 2009 Age: 73 Mr. Rice’s experience, qualifications, attributes and skills include having served as Chief Executive Officer of Andrx Corporation.
2024-04-08	Mr. Rice’s experience, qualifications, attributes and skills include having served as Chief Executive Officer of Andrx Corporation, Fort Lauderdale, Florida (specialty pharmaceuticals) (“Andrx”), from February 2004 to November 2006, when Andrx was sold to Watson Pharmaceuticals. Following the sale, Mr. Rice returned as General Manager and Majority Partner of Columbia Investments LLC, Baltimore, Maryland, which invests in local emerging businesses in Baltimore and which Mr. Rice co-founded in January 1996. He was also a Director of Par Pharmaceuticals, Woodcliff Lake, New Jersey (drug development, manufacture, and marketing) until November 2012. From January 1999 to March 2003, he was President and Chief Executive Officer of Chesapeake Biological Laboratories, Inc., Solomons, Maryland (pharmaceuticals manufacturing) (“Chesapeake”). Before co-founding Columbia Investments LLC, Mr. Rice served as Executive Vice President and Chief Operating Officer of Circa Pharmaceuticals, Inc., Copiague, New York (pharmaceuticals manufacturing) (“Circa”), from June 1993 to January 1996. Mr. Rice was also the Chief Financial Officer of Circa from June 1993 to January 1995. Prior to joining Circa, Mr. Rice spent seven years as an accountant with Deloitte & Touche LLP, an international accounting firm. He earned a Master’s degree in finance from Loyola University. He was a director of Circa from June 1993 to January 1996, a director of Chesapeake from January 1997 to January 1999 and a director of Andrx from April 2003 to November 2006.